BPC-157 Gastric Pentadecapeptide - From Stomach Juice to Research Tool

October 13, 2026

BPC-157 is a synthetic peptide that traces its origin to human gastric juice. The name stands for Body Protection Compound, and the number 157 refers to the residue numbering of the fragment within the parent protein characterized by the research group that discovered it. Before the peptide became a fixture of biohacking forums and peptide vendor catalogs, it was a laboratory curiosity isolated by a Croatian research group investigating how the stomach protects itself from its own acid.

The Discovery: Zagreb, 1975 to 1993

The story begins with Predrag Sikiric, a medical student at the University of Zagreb in Croatia. In 1975, Sikiric attended a lecture on the body's stress response and reasoned that if stress can damage the stomach, the stomach might also produce its own protective substances. This hypothesis, that the gastric lining generates compounds capable of counteracting injury, became the foundation of a research program that would span decades.

By 1983, Sikiric had assembled a team that collected human and animal gastric juice from hospitals, emergency rooms, and slaughterhouses. The goal was to isolate whatever compound was responsible for the protective effect they observed in crude gastric juice preparations. According to a 2026 STAT News profile, the group spent six years on this isolation work before identifying the active fragment.

In 1989, the team isolated a 15-amino-acid peptide from the larger protein. In 1993, Sikiric and colleagues published the foundational paper: "A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC" in the Journal of Physiology, Paris (Sikiric P, Petek M, Rucman R, Seiwerth S, et al., 1993, 87, 313-327). This paper introduced BPC-157 to the scientific literature and outlined the organoprotection hypothesis that would guide the group's subsequent work.

The Molecule: What BPC-157 Actually Is

The prefix "penta" means five, and "deca" means ten: a pentadecapeptide is a chain of fifteen amino acids. The sequence GEPPPGKPADDAGLV shows no homology to any known gut peptide. This was noted in the original publication and remains unusual. Most bioactive peptides share structural features with known signaling molecules. BPC-157 appears to be structurally distinct.

The synthetic form used in research was first produced by R. Rucman at Diagen, a Croatian biotech company, using Merrifield solid-phase peptide synthesis. The synthetic version is identical in sequence to the natural fragment but is produced under controlled laboratory conditions rather than extracted from gastric juice. This synthetic version is what every subsequent study has used.

From Gastric Protection to Broader Injury Models

The initial research focused on what the name implies: body protection. The Zagreb group tested BPC-157 against gastric lesions induced by ethanol, NSAIDs, and restraint stress in rats. The peptide consistently reduced lesion size and accelerated mucosal healing in these models.

Over the following decade, Sikiric's group expanded the scope of investigation considerably. They tested BPC-157 in models of tendon transection, muscle crush injury, nerve damage, vascular injury, and several other tissue types. The peptide showed positive effects across most of these models, which is part of what attracted attention outside the gastric research community. A 2025 review in Pharmaceuticals cataloged over 100 published studies investigating BPC-157 in various preclinical models.

This breadth of reported activity is both the peptide's appeal and the source of legitimate scientific skepticism. A single 15-amino-acid fragment showing beneficial effects across tendons, muscles, nerves, blood vessels, the gut, the brain, and the liver raises questions about mechanism specificity. The proposed mechanisms involve the nitric oxide system, VEGF-mediated angiogenesis, and growth factor receptor pathways, but a unifying mechanism that explains all reported effects has not been established.

The Commercial Development That Stalled

From 1993, the Zagreb pharmaceutical company PLIVA, working with Parke-Davis, developed BPC-157 for potential clinical use. Two small human trials for ulcerative colitis were conducted in the early 2000s. The second trial reported a positive effect that did not reach statistical significance.

When GlaxoSmithKline acquired PLIVA's research institute in 2006, the BPC-157 program was shelved. The rights returned to Sikiric in 2009. No pharmaceutical company has since pursued large-scale human trials. We find this gap between extensive animal data and minimal human data to be the central issue with BPC-157 as it stands today. The preclinical record is unusually large for a peptide that has never completed a Phase III trial.

The Stability Question

One of BPC-157's notable properties is its stability in gastric acid. Most peptides degrade rapidly in the low-pH environment of the stomach, which is why oral bioavailability of peptide drugs is generally poor. BPC-157, having evolved in gastric juice, shows unusual resistance to acid degradation. This property has fueled interest in oral administration, and several vendors now sell oral BPC-157 formulations. However, acid stability does not guarantee systemic bioavailability. Whether the intact peptide reaches target tissues after oral administration in humans is not established by published data.

What We Know and What We Do Not

BPC-157 has a clear origin story grounded in a reasonable hypothesis: the stomach produces protective compounds, and isolating those compounds might have therapeutic value. The foundational science is legitimate. Sikiric's group has published consistently in peer-reviewed journals for over 30 years.

What is missing is the bridge between animal models and human medicine. The two small ulcerative colitis trials were inconclusive. No large human trial has been completed for any indication. The jump from "reduces gastric lesions in rats" to the broader claims circulating online happened in forums and vendor marketing, not in clinical research.

For those comparing BPC-157 with TB-500 or evaluating whether the two peptides address different mechanisms, we have detailed the available evidence on our stacking benefits page and comparison page.